Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
08/28/2012 | 10:06pm CET

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at [email protected]

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
Valeurs citées dans l'article
ChangeLast1st jan.
ABBOTT LABORATORIES -1.75% 59.12 Delayed Quote.2.12%
JOHNSON & JOHNSON -1.71% 130.87 Delayed Quote.-7.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
02/20ABBOTT LABORATORIES : Declares 377th consecutive quarterly dividend
02/19ABBOTT LABORATORIES PAKISTAN : Board of directors meeting of Abbott Laboratories..
02/16ABBOTT : Declares 377th Consecutive Quarterly Dividend
02/15ABBOTT LABORATORIES : ' Trademark Application for "DRAGONFLY OPSTAR" Filed
02/15ABBOTT LABORATORIES : ' Trademark Application for "WHISPER" Filed
02/15ABBOTT LABORATORIES : Trademark Application for "READIFLEX" Filed by Abbott Labo..
02/15ABBOTT LABORATORIES : ' Trademark Application for "PEDIALYTE ADVANCEDCARE" Filed
02/13LIFE SCIENCE REAGENT MARKET VALUE SH : Life Science Reagent Market Overview & In..
02/09BODY SENSOR MARKET PROFESSIONAL SURV : The report segments the body sensor marke..
02/08ABBOTT LABORATORIES : Trademark Application for "ST. JUDE MEDICAL" Filed by Abbo..
More news
News from SeekingAlpha
02/16Abbott Laboratories declares $0.28 dividend 
02/16Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update 
02/15THE DIVIDEND GROWTH PORTFOLIO TO GRO : Getting Up When Life Knocks You Down 
02/14Repairing The Foundations Of The Dividend House And Millennial Millions DGI P.. 
02/14My Dividend Achievers Finally Pass The Index 
Financials ($)
Sales 2018 30 847 M
EBIT 2018 6 456 M
Net income 2018 3 041 M
Debt 2018 15 102 M
Yield 2018 1,86%
P/E ratio 2018 39,00
P/E ratio 2019 32,23
EV / Sales 2018 3,88x
EV / Sales 2019 3,56x
Capitalization 105 B
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 68,2 $
Spread / Average Target 13%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Randel W. Woodgrift VP-Abbott Medical Devices Cardiovascular
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359